Amylin, Eli Lilly and Alkermes has reported positive results from a study comparing subjects randomized to either exenatide once weekly or Lantus (insulin glargine). The patients randomized to
Merck & Co.’s integrase inhibitor, Isentress (raltegravir), was as effective as efavirenz at maintaining viral load suppression to undetectable levels and improving CD4 counts in previously untreated patients
The Dutch Medicines Evaluation Board (MEB) has informed Eurand that the Decentralized Procedure (DCP) for registration of Paracetamol 250 and 500mg Orodispersible Tablets (ODT) in several EU countries,
Provectus has initiated a new phase 2 clinical trial of PH-10 for psoriasis, involving daily dosing of patients for 28 days. Preliminary analysis of the data from the
Cytokine has initiated the phase I study of CPSI-2364, its orally active, smallmolecule inhibitor of the production of TNF-alpha and other pro-inflammatory cytokines. CPSI-2364 is a chemically-modified form
Human Genome (HGS) and GlaxoSmithKline (GSK) has reported that Benlysta (belimumab) met its primary endpoint by achieving a significant improvement in patient response rate versus placebo in BLISS-52.
Ardea Biosciences has initiated phase 2b clinical trial of RDEA594 for the management of hyperuricemia and gout. Reportedly, the randomized, double-blind, placebo-controlled, dose-response study will evaluate the safety
Natus Medical has bagged a contract to provide its Newborn Hearing Screening Data Management service to the California department of health care services. The company is likely to
AlphaVax has completed process development and preclinical immunogenicity studies of its H1N1 (swine) influenza vaccine and will manufacture clinical trial material by the end of the month. The
Bionovo has announced that a study of the gene regulation in multiple cell lines by several of their estrogen receptor beta (ERb) candidates, will be published in Public
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.